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Idiopathic pulmonary fibrosis (IPF) is a chronic fibro-proliferative disease characterized 
by poor prognosis, with a mean survival of ~2–3  years after definite diagnosis. The 
cause of IPF is still unknown but it is a heterogeneous condition in which the aberrant 
deposition of extracellular matrix leads to extensive lung remodeling. This remodeling 
is a consequence of inflammatory responses, but the mechanisms involved are poorly 
understood. In this study, we first analyzed a bleomycin-induced mouse model, which 
showed that higher expression of IL-1β, but not IL-18, was correlated to pulmonary cell 
infiltration and fibrosis. Then, we found that peripheral blood mononuclear cells (PBMCs) 
from IPF patients released IL-1α and IL-18 in a NLRP3- and calpain-independent manner 
after LPS ± ATP stimulation. Instead, the activation of the absent in melanoma 2 (AIM2) 
inflammasome induced the release of IL-1α in a caspase-1-/caspase-8-independent 
manner; whereas IL-18 release was caspase-1 dependent. These effects correlated 
with the release of the pro-fibrotic TGF-β, which was induced by AIM2 activation in a 
caspase-1- and TLR4-independent manner, but dependent on IL-1α. In this context, the 
activation of AIM2 induced the release of caspase-4 from IPF-derived PBMCs, which 
correlated with the mRNA levels of this caspase that was higher in IPF than in healthy 
PBMCs. In conclusion, our findings identify a novel molecular mechanism whereby 
the activation of AIM2 could lead to the activation of the non-canonical inflammasome 
(caspase-4 dependent) that induces the release of IL-1α responsible for the release of 
TGF-β from PBMCs of IPF patients.
Keywords: idiopathic pulmonary fibrosis, absent in melanoma 2 inflammasome, il-1α, il-18, caspase-4
2Terlizzi et al. AIM2 Is Pro-Fibrotic in IPF-Derived PBMCs
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 670
inTrODUcTiOn
Idiopathic pulmonary fibrosis (IPF), a severe form of inter-
stitial disease, is a chronic and irreversible respiratory disease 
characterized by inflammation and fibrosis (1, 2). Despite the 
etiology of IPF is still not known, genetic factors, infections, 
inhalation of fibers and particles (cigarette smoke and asbestos), 
and gastroesophageal reflux were suggested as possible risk fac-
tors for the development of pulmonary fibrosis (3). Nevertheless, 
dysfunction in the process of tissue repairing of epithelial cells 
(4), fibroblast activation, and differentiation into myofibroblasts 
(5) with the ensuing extensive extracellular matrix deposition, 
are key processes involved in the fibrotic process (4, 5). In this 
context, although postulated, the role of chronic inflammation 
still remains elusive. Recent data suggest that the pathophysiol-
ogy of IPF is more related to fibroblast dysfunction than to 
dysregulated inflammation (6). In support, no pharmacological 
modulation of the immune system seems to be as effective (7). 
In contrast, human data support the role of inflammation in that 
pro-inflammatory cytokines and immune infiltrates character-
ize IPF-derived lungs (8). Moreover, repeated danger stimuli 
(i.e., silica, asbestos) trigger chronic inflammatory patterns that 
lead to progressive decline of pulmonary function and architec-
ture (2). In this context, because danger stimuli are well-known 
activator of Nod-like receptors (NLR) which are involved in the 
inflammasome activation, the goal of this study was to evaluate the 
involvement of this latter complex. The inflammasome is a multi-
protein complex that comprises the assembly of NLRs or HIN200 
family receptors, such as absent in melanoma 2 (AIM2), able to 
bind the adaptor apoptosis-associated speck-like protein contain-
ing a carboxyterminal domain that induces the auto-cleavage of 
caspase-1 and the activation of IL-1-like cytokines (9). Alternative, 
non-canonical inflammasomes have also been described, which 
engage caspase-8 or caspase-11 (also known as caspase-4 in 
humans) (9, 10), which in turn induce inflammasome-dependent 
caspase-1 activation and inflammasome independent, pyroptosis-
like cell death, via the release of such “alarmins” as IL-1α (9).
To note, IL-1β and IL-18, related to the inflammasome acti-
vation, have been associated with the development of IPF (11). 
During acute exacerbation of IPF, alveolar macrophages (AMs) 
and type II pneumocytes produce high levels of IL-1β in a mouse 
model of bleomycin-induced fibrosis (12). Moreover, the levels 
of mRNA for IL-1β and IL-18 were augmented in AMs isolated 
by bronchoalveolar lavage (BAL), and lung, respectively, from 
the same patients (13). In addition, IL-1β is also able to induce 
the production of TGF-β, thus it is plausible that the inflamma-
some is involved in fibroblast activation and differentiation into 
myofibroblasts (14).
In this study, we found that IPF-derived peripheral blood mon- 
onuclear cells (PBMCs) were able to release IL-1α and IL-18 after 
the stimulation with Poly dA:dT, an AIM2 ligand. In particular, we 
found that the activation of AIM2 led to IL-18 release in a canoni-
cal manner, in that Ac-Y-VAD-cmk, caspase-1 inhibitor, inhibited 
the release of IL-18 after Poly dA:dT administration. In contrast, 
the release of IL-1α was not caspase-1 or caspase-8 dependent, 
implying the involvement of caspase-4 as non-canonical pathway. 
Indeed, the activation of AIM2 led to the extracellular release of 
caspase-4 that was not correlated to cell death, rather to IL-1α 
release, responsible for TGF-β secretion in IPF-derived PBMCs.
MaTerials anD MeThODs
animal Model
All animal procedures were approved by the Animal Care and 
Ethics Committee at the University of Newcastle, Australia. Experi - 
mental pulmonary fibrosis was induced by intranasal administra-
tion of one dose of bleomycin sulfate (MP Biomedical) to 6–8 weeks 
Balb/C mice, 0.05 U/mouse, as previously described (15). Control 
groups received an equal volume of sterile PBS. Tissue collection 
was performed 28 days after bleomycin treatment.
Bronchoalveolar lavage Fluid (BalF)
Mouse multi-lobed lungs were tied off, and BALF was collected 
from the single left lung lobe by washing with PBS (2 × 500 µl). 
Cells were pelleted (150 g, 5  min) and resuspended in red cell 
lysis buffer. Remaining cells were cytocentrifuged (300 g, 10 min) 
onto microscope slides. BALF slides were stained with May–
Grunwald–Giemsa, and differential counts were enumerated 
according to morphological criteria using light microscopy as 
previously described (15).
human samples
We used blood from healthy volunteers and IPF patients recruited 
at the “Monaldi-Azienda Ospedaliera (AORN)-Ospedale dei Colli” 
Hospital in Naples, Italy, after their approval according to the 
Review Board of the hospital and the patients’ informed consent. 
In addition, all experimental protocols were, as stated above, 
approved and performed in accordance with the guidelines and 
regulations provided by the Review Board (protocol n. 422/2017). 
All the subjects were 50 ±  10  years of age and had no history 
of allergic diseases or chronic respiratory conditions. Blood was 
collected and used within 24 h.
isolation of human PBMcs
Peripheral blood mononuclear cells were isolated according to 
Ficoll’s protocol as already reported (16). Briefly, blood (5 ml) was 
mixed with cell medium (5 ml) supplemented with sole antibio- 
tics and Ficoll medium (Life Sciences, Italy). PBMCs layer was 
collected and platelets were separated by centrifugation at 149 g  
for 10 min. PBMCs were then collected in cell medium, plated, and 
treated for 1, 3, 5, or 24 h accordingly. PBMCs were treated with the 
following substances: LPS 0.1 µg/ml, ATP 0.5 mM, Ac-Y-VAD-cmk 
(y-VAD) 1 µg/ml, glybenclamide (Gly) 1 µM, MDL28170 (MDL) 
10 µM, Poly dA:dT (dA:dT) 1 µg/ml, z-IETD-fmk (IE) 0.5 µg/ml, 
nintedanib (10 nM), and pirfenidone (0.1 µg/ml).
cytokine Measurements
IL-1α, IL-18, and TGF-β were measured in cell-free supernatants 
using commercially available enzyme-linked immunosorb-
ent assay kits (ELISAs) (eBioscience, CA, USA; R&D Systems, 
MN, USA). The released form of caspase-4 was analyzed using 
a kit patented by ImmunePharma s.r.l. (RM2014A000080 and 
PCT/IB2015/051262) (Department of Pharmacy, University of 
Salerno, Italy).
FigUre 1 | Murine lungs of bleomycin-induced fibrosis express higher levels 
of IL-1β. Intranasal administration of one dose of bleomycin sulfate (0.05 U/
mouse) to Balb/C mice increased (a) bronchoalveolar lavage fluid (BALF) 
total cell count (p = 0.019), (B) macrophages (*p = 0.019), (c) neutrophils 
(p = 0.876), and (D) lymphocytes (**p = 0.0095). Analysis of mRNA levels of 
(e) IL-1β (*p = 0.0198) and (F) IL-18 (p = 0.8159) in the whole lung of 
bleomycin-treated mice. Data are represented as means ± SEM (n = 4–8). 
Statistically significant differences were determined by Mann–Whitney test  
for BALF and unpaired Student’s t-test for mRNA analysis.
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lDh levels
The levels of lactate dehydrogenase were measured by using a 
commercially available kit (Sigma, Italy) following the manufac-
turer’s instructions. Data were expressed as OD values.
rT-Pcr
Total RNA was isolated from PBMCs by using the RNA extrac-
tion kit according to the manufacturer’s instructions (Qiagen, 
Milan, Italy). Reverse transcription was performed by using 
first-strand cDNA synthesis kit (Qiagen, Milan, Italy) followed by 
PCR. Thermal cycling conditions were as follow: 5 min at 95°C, 
followed by 45 cycles of 30 s at 95°C, 60 s at 58°C, and 30 s at 68°C. 
Primer pairs were as follow:
Caspase-4→ Forward 5′-TCCCTGGGCAAAGATTTCCT-3′
Reverse 5′-GTCCAGCCTCCATATTCGGA-3′
β-actin→ Forward 5′-ACTCTTCCAGCCTTCCTTCC-3′
Reverse 5′-CGTACAGGTCTTTGCGGATG-3′
In other set of experiments, we used whole mouse lungs, which 
were excised and homogenized using a tissue stick homogenizer 
(BioSpec). Total RNA was extracted using TRIzol (Invitrogen) 
according to the manufacturer’s instructions. RNA (1 µg) from 
whole lungs was reverse transcribed using Bioscript (Bioline) and 
random hexamer primers (Invitrogen). The mRNA expression of 
IL-1β and IL-18 was determined using real-time PCR (Biorad) 
and compared with the reference gene hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) as previously described (17). 
Primer pairs were as follow:
IL-1β → Forward 5′-TGGGATCCTCTCCAGCCAAGC-3′
Reverse 5′-AGCCCTTCATCTTTTGGGGTCCG-3′
IL-18→ Forward 5′-TCAGACAACTTTGGCCGACT-3′
Reverse 5′-CAGTCTGGTCTGGGGTTCAC-3′
HPRT→ Forward 5′-AGGCCAGACTTTGTTGGATTTGAA-3′
Reverse 5′-CAACTTGCGCTCATCTTAGGCTTT-3′
Flow cytometry analysis
NLRP3 and AIM2 expression was performed by flow cytometry 
(BD FacsCalibur, Milan, Italy) using the following antibodies: 
NLRP3-FITC, AIM2-FITC, and CD14-PE (eBioscience, CA, USA).
statistical analysis
Data are reported as the median ± interquartile range. Statistical 
differences were assessed with one-way ANOVA followed by 
multiple comparison post-test or Student’s t-test (where appro-
priate) followed by Mann–Whitney test. p-Values less than 0.05 
were considered as significant.
resUlTs
lungs of Bleomycin-induced Fibrosis 
express higher levels of il-1β
To understand the role of the inflammasome in pulmonary 
fibrosis, we used an experimental pulmonary fibrosis, induced 
by intranasal administration of one dose of bleomycin sulfate 
(0.05  U/mouse) to Balb/C mice, as previously described (15). 
Control groups received an equal volume of sterile PBS. BALF 
showed that lungs of fibrotic bleomycin-treated mice had higher 
cell count (total cells (×104): PBS 2.23 ± 0.31; Bleo 6.71 ± 2.79) 
than PBS-treated mice (Figure  1A). Differential counts of 
BALF-derived cells showed that bleomycin-treated mice were 
characterized by higher presence of macrophages (Figure  1B), 
neutrophils (Figure 1C), and lymphocytes (Figure 1D) at 28 days 
after bleomycin treatment. Interestingly, the mRNA expression 
levels of IL-1β (Figure 1E), but not of IL-18 (Figure 1F), was sig-
nificantly higher (p = 0.0198; PBS 0.14 ± 0.02; Bleo 0.23 ± 0.03) 
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in the whole lung of bleomycin-treated mice than PBS-treated 
mice, implying the involvement of the inflammasome in this 
experimental model.
human PBMcs From iPF Patients release 
il-1α in an nlrP3 inflammasome-
independent Manner
The role of inflammasomes has been partially described in chro-
nic respiratory diseases (10), but its role in IPF is still not clear. To 
investigate the potential role of these complexes in this pathology, 
PBMCs from non-IPF healthy volunteers, and IPF age-matched 
patients were isolated. We observed that the stimulation of cells 
with LPS (0.1 µg/ml), a TLR4 ligand that induces NLRP3 activa-
tion according to the two-signal model (9), induced a significant 
release of IL-1α from IPF-derived PBMCs (Figure 2A). Conversely, 
the same effect was not evident for PBMCs derived from healthy 
individuals, although the basal levels of IL-1α were higher com-
pared with IPF controls (Figure 2A). Interestingly, treatment with 
LPS + ATP, NLRP3 activators, significantly (p < 0.01) increased 
the levels of IL-1α release from IPF but not from healthy PBMCs 
(Figure 2A), implying the involvement of NLRP3 in IL-1α release 
from IPF-derived PBMCs. To understand the involvement of 
the NLRP3/caspase-1-dependent inflammasome in the release 
of this cytokine, we tested the effect of Ac-Y-VAD-cmk (y-Vad, 
1  µg/ml), a well-known caspase-1 pharmacological inhibitor 
(18) and Gly (1 µM), an inhibitor of NLRP3 inflammasome (19). 
Surprisingly, administration of y-Vad did not alter IL-1α release 
after LPS +  ATP treatment (Figure  2B), implying that IL-1α 
release was not caspase-1 dependent. Similarly, IL-1α levels were 
not reduced after Gly treatment compared with the positive 
control (LPS + ATP, Figure 2C), supporting the hypothesis that 
LPS + ATP-induced IL-1α release was not NLRP3 dependent.
In this context, Gross and colleagues showed that IL-1α was 
not universally inflammasome dependent. Rather, they showed 
Rather, they showed that IL-1a secretion was dependent on 
calpain like proteases, activated by the influx of calcium through 
the opening of cation channels (20). Therefore, we inhibited the 
calpain system using MDL28170 (MDL, 10 µM). However, this 
did not statistically alter IL-1α release (Figure 2D).
To rule out cell death after dA:dT administration, we measured 
the levels of extracellular LDH. Treatment of IPF-derived PBMCs 
with dA:dT, in the presence or not of Gly, y-Vad, and MDL, 
did not alter the levels of LDH among the groups compared with 
the control (basal) levels (Figure S1 in Supplementary Material).
Moreover, the administration of a caspase-8 inhibitor, z-IETD-
fmk (IE, 0.5 µg/ml) did not alter IL-1α levels when IPF-derived 
PBMCs were treated with LPS ± ATP (Figure 2E).
Because caspase-1 and caspase-8 were not involved in IL-1α 
release after LPS treatment, and because it was reported that 
caspase-4 is the intracellular receptor for LPS, we investigated the 
non-canonical inflammasome pathway (9, 21). To date, no spe-
cific inhibitor is actually available to inhibit caspase-4. Therefore, 
we performed experiments in an indirect manner by inhibiting 
TLR4, which should allow LPS to enter the cells and induce 
caspase-4 activation (9, 21). The blockade of TLR4 did not alter 
IL-1α release from IPF-derived PBMCs after LPS ± ATP addition 
(Figure 2F), implying the involvement of caspase-4. To confirm 
our hypothesis, we found that NLRP3 expression in CD14+ PBMCs 
was significantly lower in IPF than healthy subjects (Figure 2G).
Taken together, these data suggest that IPF-derived PBMCs 
are able to release IL-1α after LPS and/or LPS + ATP stimulation 
in an NLRP3-/caspase-1-/caspase-8-, TLR4-, and calpain-inde-
pendent manner, but most likely via the involvement of caspase-4.
activation of aiM2 leads to the release of 
il-1α From iPF PBMcs in a caspase-1- 
and caspase-8-independent Manner
In our previous study, we demonstrated that the release of 
IL-1α from lung tumor-associated plasmacytoid dendritic cells 
was AIM2 inflammasome dependent and promoted tumor cell 
proliferation in the lung (19). Therefore, we analyzed the pos-
sible involvement of AIM2 inflammasome in IL-1α release from 
IPF-derived PBMCs. The stimulation of PBMCs with Poly dA:dT 
(dA:dT, 1 µg/ml), an AIM2 ligand, significantly increased IL-1α 
levels (Figure  3A). Similar to LPS ±  ATP, the same effect was 
not observed from the healthy PBMCs from which IL-1α basal 
levels were higher than IPF-derived PBMCs (Figure  3A). To 
understand the molecular mechanism associated with AIM2-
dependent IL-1α release, we treated the cells with caspase-1 
inhibitor, y-VAD, or caspase-8 inhibitor, IE, in the presence 
or not of dA:dT. The pharmacological inhibition of caspase-1 
(Figure 3B) or caspase-8 (Figure 3C) did not reduce IL-1α levels, 
rather, its release was further increased compared with treatment 
with dA:dT alone.
Moreover, because it was described that the intracellular LPS 
receptor is represented by caspase-4 (9, 21), in order to evaluate 
whether this enzyme was correlated to IL-1α release, we neutral-
ized TLR4 by means of an antibody and measured the release 
of IL-1α under dA:dT stimulation. The neutralization of TLR4 
did not alter the release of IL-1α after the addition of dA:dT 
(Figure  3D). We observed the same effect after LPS  +  ATP 
stimulation (data not shown).
The isotype control IgG did not alter the levels of basal IL-1α 
(15.7 ± 2.56 pg/ml, data not shown). These results indicate that 
AIM2 inflammasome activation in IPF-derived PBMCs leads to 
IL-1α release in a caspase-1-/caspase-8- and TLR4-independent 
manner, implying the involvement of another mechanism(s), as 
observed for LPS ± ATP (Figure 2), most likely due to the non-
canonical inflammasome (caspase-4 dependent).
activation of aiM2 leads to the release  
of il-18 From iPF PBMcs in a caspase- 
1-Dependent Manner
Despite a role for IL-18 being reported in many biological 
processes, its contribution to fibrosis is unclear, with both pro- 
and anti-fibrotic effects having been demonstrated (11, 22). 
The addition of LPS or ATP or LPS + ATP did not increase the 
release of IL-18 from PBMCs from either healthy or IPF patients 
(Figure  4A). In sharp contrast, IL-18 levels were significantly 
increased after the stimulation of AIM2 via dA:dT administra-
tion to both healthy- and IPF-derived PBMCs (Figure 4B). To 
understand whether AIM2 was expressed, we performed flow 
cytometry analysis on CD14+ PBMCs. We did not observe 
FigUre 2 | Idiopathic pulmonary fibrosis (IPF)-derived peripheral blood mononuclear cells (PBMCs) release IL-1α in a NLRP3/caspase-1-/caspase-8-/TLR4- and 
calpain-independent manner. LPS (0.1 μg/ml) ± ATP (0.5 mM) stimulation (5 h) of PBMCs obtained from IPF patients, significantly increased IL-1α release compared 
with control; no effect was observed in healthy subjects-derived cells after LPS ± ATP addition (a). (B) The inhibition of caspase-1 by means of Ac-Y-VAD-cmk 
(y-VAD, 1 µg/ml) did not induce a reduction of IL-1α release, even after LPS and/or ATP addition. IL-1α levels were not altered after the addition of glybenclamide 
(Gly, 1 µM) (c) or MDL28170 (MDL, 10 µM) (D) to LPS ± ATP compared with positive control. Similarly, the inhibition of caspase-8 by means of z-IETD-fmk (IE, 
0.5 µg/ml) (e) and the blockade of TLR4 (F) did not alter the release of IL-1α after dA:dT addition. (g) Expression of NLRP3 in CD14+ PBMCs. Data are represented 
as median ± interquartile range (n = 13). Statistically significant differences were determined by one-way ANOVA followed by Bonferroni’s multiple comparison 
post-test or by Student’s t-test and Fischer’s exact test as appropriate.
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statistical differences for AIM2 expression between healthy and 
IPF CD14+ PBMCs (Figure 4C).
To define the roles of caspase-1-dependent canonical inflam-
masome versus caspase-8-dependent non-canonical inflamma-
some, specific pharmacological inhibitors were used. Contrary 
to what observed for IL-1α (Figures  3B,C), IL-18 release was 
abrogated after the addition of y-VAD to dA:dT (Figure 4D); in 
contrast, the pharmacological inhibition of caspase-8 with IE, did 
not alter IL-18 levels after dA:dT treatment (Figure 4D) imply-
ing that caspase-8 was not involved. Moreover, the inhibition 
of TLR4 did not alter IL-18 release after dA:dT administration 
(Figure 4E).
Taken together, these data indicate that IL-18 release from 
IPF-derived PBMCs was AIM2/caspase-1 dependent following 
the activation of the canonical inflammasome compared with 
IL-1α.
FigUre 3 | IL-1α release from idiopathic pulmonary fibrosis (IPF)-derived peripheral blood mononuclear cells (PBMCs) is induced after absent in melanoma 2 (AIM2) 
inflammasome activation. (a) Poly dA:dT (dA:dT, 1 µg/ml) stimulation (5 h) of PBMCs obtained from IPF patients, significantly increased IL-1α release compared  
with control; no effect was observed in healthy subjects-derived cells after dA:dT addition. The inhibition of caspase-1 by means of Ac-Y-VAD-cmk (y-VAD, 1 µg/ml) 
(B) or caspase-8 by means of z-IETD-fmk (IE, 0.5 µg/ml) (c) or TLR4 blockade (D) did not affect IL-1α release, even after dA:dT treatment. Data are represented  
as median ± interquartile range (n = 13). Statistically significant differences were determined by one-way ANOVA followed by Bonferroni’s multiple comparison 
post-test.
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activation of aiM2 inflammasome induces 
TgF-β release From iPF-Derived PBMcs 
in a non-canonical Manner
TGF-β has long been proposed as a key molecule in the patho-
genesis of lung fibrosis (23, 24), thus we examined its role in 
our experimental conditions. We found that the stimulation 
with LPS + ATP tended (not statistically significant) to increase 
TGF-β levels (Figure 5A) from IPF-derived PBMCs. In contrast, 
the stimulation of AIM2 with dA:dT significantly increased the 
release of TGF-β from IPF-derived PBMCs after 24 h of treatment 
(Figure 5B).
To examine the molecular mechanisms, we treated the cells 
with a caspase-1 inhibitor. The inhibition of caspase-1 with y-Vad 
did not alter TGF-β levels after dA:dT administration (Figure 5C), 
suggesting that AIM2-induced TGF-β release from IPF patients-
derived PBMCs was caspase-1 independent.
It is well known that TLR4 signaling results in augmented 
TGF-β responses with increased matrix production and progres-
sive connective tissue remodeling (25), and that TLR4 stimulation 
controls inflammasome activation (9, 26). Moreover, because we 
already observed that the neutralization of TLR4 did not alter 
the release of IL-1α after the addition of dA:dT (Figure 3D), we 
tested the levels of TGF-β in these conditions. We observed that 
the release of TGF-β after the activation of AIM2 via dA:dT was 
not altered by the neutralization of TLR4 (Figure 5D). The isotype 
control IgG did not alter the levels of basal TGF-β (107 ± 28 pg/ml, 
data not shown). In sharp contrast, the neutralization of IL-1α by 
using a monoclonal antibody (isotype control IgG), significantly 
reduced the release of TGF-β after dA:dT treatment (Figure 5E), 
implying that IL-1α is involved in TGF-β release.
To further explore the molecular mechanism that leads to 
TGF-β release from IPF-derived PBMCs, we treated the cells 
with the two drugs that are actually used in therapy, nintedanib 
FigUre 4 | IL-18 release from idiopathic pulmonary fibrosis (IPF)-derived peripheral blood mononuclear cells (PBMCs) is absent in melanoma 2 (AIM2)/caspase-1 
dependent. (a) LPS ± ATP treatment (5 h) of PBMCs did not induce a significant increase of IL-18 levels both in IPF patients and healthy subjects. (B) Poly dA:dT 
(dA:dT, 1 µg/ml) stimulation (5 h) of PBMCs isolated from IPF patients and healthy subjects significantly increased IL-18 release compared with respective control. 
(c) Expression of AIM2 in CD14+ cells. (D) Caspase-1 inhibition reduced IL-18 release after dA:dT addition, unlike caspase-8 inhibition. Similarly, TLR4 blockade  
did not alter IL-18 release after dA:dT administration (e). Data are represented as median ± interquartile range (n = 13). Statistically significant differences were 
determined by one-way ANOVA followed by Bonferroni’s multiple comparison post-test.
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(10 nM), a tyrosine kinase inhibitor, and pirfenidone (0.1 µg/ml). 
Surprisingly, neither nintedanib (Figure  5F) nor pirfenidone 
(Figure  5G) reduced the levels of TGF-β from IPF-derived 
PBMCs.
Taken altogether, these data imply that the activation of AIM2 
leads to IL-1α that promotes TGF-β release from IPF-derived 
PBMCs.
activation of aiM2 leads to caspase-4 
release From iPF PBMcs
In our previous data, we showed that the activation of AIM2 
with dA:dT led to the release of IL-1α and TGF-β in a caspase-1, 
caspase-8-, and calpain-independent manner; whereas IL-18 was 
released in a caspase-1-dependent manner. Moreover, because in 
our previous data we found that caspase-1, caspase-8, calpain I/
FigUre 5 | The activation of absent in melanoma 2 inflammasome induces the release of the pro-fibrotic TGF-β. (a) Treatment with LPS ± ATP for 24 h induced  
the release of TGF-β from idiopathic pulmonary fibrosis (IPF) peripheral blood mononuclear cells (PBMCs), although not was a statistical significant manner. (B) Poly 
dA:dT (dA:dT) stimulation significantly increased the release of TGF-β from IPF-derived PBMCs. The inhibition of caspase-1 with Ac-y-Vad (y-Vad) did not reduce 
TGF-β release after (c) dA:dT treatment. The neutralization of TLR4 did not reduce TGF-β release after dA:dT treatment (D). Instead, the neutralization of IL-1α 
significantly reduced TGF-β release (e). In sharp contrast, the addition of nintedanib (10 nM) (F) or pirfenidone (g) did not alter dA:dT-induced TGF-β release.  
Data are represented as median ± interquartile range (n = 13). Statistically significant differences were determined by one-way ANOVA followed by Bonferroni’s 
multiple comparison post-test or Student’s t -test and Fischer’s exact test as appropriate.
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II axis, and TLR4 activity were not involved in IL-1α release, we 
went on by analyzing the involvement of caspase-4.
We first analyzed the levels of mRNA for caspase-4 in PBMCs 
obtained from IPF patients and healthy subjects. Caspase-4 
mRNA levels were very low in healthy non-IPF, control cells 
(0.4 ± 0.31, Figure 6A). In contrast, the levels were noticeably 
increased in PBMCs from IPF patients (4.357 ± 0.86) (Figure 6A) 
compared with healthy PBMCs, suggesting an important role for 
this protease during pulmonary fibrosis. Notably, however, no 
increases in mRNA levels of caspase-4 were detected after LPS or 
dA:dT stimulation in IPF PBMCs (Figure 6A). In order to under-
stand the potential involvement of caspase-4 in our experimental 
conditions, we used a patented ELISA kit that detects the released 
form of caspase-4. Interestingly, the addition of dA:dT to IPF-
derived PBMCs significantly increased the release of caspase-4 
(Figure 6B).
Taken together, these data, although not in a direct manner for 
the absence of a specific inhibitor, suggest that the activation of 
AIM2 leads to caspase-4 release responsible of IL-1α-dependent 
pro-fibrotic TGF-β release (Figure 7).
FigUre 6 | Caspase-4 extracellular release from idiopathic pulmonary 
fibrosis (IPF) peripheral blood mononuclear cells (PBMCs) after AIM2 
inflammasome activation. (a) PBMCs derived from IPF patients showed 
higher basal levels of caspase-4 mRNA compared with healthy subjects.  
(B) Caspase-4 release in the supernatant of IPF-derived PBMCs increased 
after 5 h of treatment with LPS and dA:dT. Data are represented as 
median ± interquartile range (n = 13). Statistically significant differences were 
determined by one-way ANOVA followed by Bonferroni’s multiple comparison 
post-test.
FigUre 7 | The activation of the absent in melanoma 2 (AIM2) 
inflammasome induce the release of caspase-4 which leads to IL-1α  
release, responsible of TGF-β release in idiopathic pulmonary fibrosis- 
derived peripheral blood mononuclear cells.
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DiscUssiOn
The role of the inflammasome in the development/exacerbation 
of IPF has been suggested, although it is still elusive. In our 
study, we found that the activation of AIM2 inflammasome in 
IPF PBMCs led to IL-1α, but not IL-1β, and TGF-β release in 
a TLR4-/caspase-1-/caspase-8-/calpain-independent manner, 
concomitantly to caspase-4 extracellular release. IL-18, instead, 
as observed in healthy cells, was AIM2/caspase-1 dependent. 
Notably, treatment of IPF PBMCs with LPS and/or LPS + ATP, 
well-known activators of NLRP3, led to the release of IL-1α in an 
NLRP3-/caspase-1/caspase-8-/TLR4- and calpain-independent 
manner, leading to a slight increase of caspase-4 release.
Several published data report NLRP3 as involved in lung 
fibrosis in both experimental and human samples. In our study, 
we found that the levels of NLRP3 were lower in IPF-derived 
PBMCs, explaining why its activation via LPS +  ATP was not 
responsible for both IL-18 and IL-1α release. In addition, in order 
to further evaluate the role of NLRP3, we used the diazoxide, as 
an inducer of NLRP3 in that it increases K + influx (19). Similarly, 
we did not observe an increase in IL-1α and TGF-β (data not 
shown) from IPF-derived PBMCs, supporting that the lower 
expression of NLRP3 in IPF-derived PBMCs is not functional. 
Instead, experimental animal models showed that NLRP3 ko 
mice were protected from mechanical ventilation- (27) and 
silica- (28), asbestos-induced pulmonary fibrosis (13). The dis-
crepancy with the latter data and ours may reflect the difference 
between human and mouse samples. Indeed, in our experimental 
model of bleomycin-induced pulmonary fibrosis (measured by 
collagen deposition around the airways) (15), we observed that 
IL-1β, rather than IL-18, as observed in humans, is upregulated 
in mRNA levels after bleomycin treatment. In contrast, treatment 
of human PBMCs with both LPS ± ATP and/or Poly dA:dT did 
not induce detectable levels of IL-1β (data not shown) in our 
experimental conditions (5  h of treatment). This result may 
underlie an impairment in NLRP3 response when LPS ±  ATP 
were added. In support, Lasithiotaki et al. reported that NLRP3 
was not involved in IPF patients (29). Similarly, we did not 
observe any inhibition of IL-1α and IL-18 after the addition of 
Gly, an inhibitor of NLRP3, implying that these cytokines are not 
NLRP3-related in IPF PBMCs. In the same manner, the release of 
these cytokines was not altered after caspase-1/caspase-8 inhibi-
tion in IPF-derived PBMCs. Because caspase-8, besides caspase-1, 
are reported as understream NLRP3 activation, we can conclude 
that because NLRP3 is not involved in the release of IL-1α and 
IL-18 in PBMCs of IPF patients, it is likely that LPS triggers the 
intracellular caspase-4 (9, 21) that is released (although not in 
a statistically different manner) after LPS addition. Instead, the 
release of caspase-4 was more evident when AIM2 (upstream) 
was activated. However, in this context, it has to be noted that the 
stimulation of healthy PBMCs with LPS ± ATP did not induce 
the release of IL-1α and IL-18, although a higher expression of 
NLRP3 in healthy PBMCs. We can speculate that this phenomenon 
could be related to a protective regulatory pathway that does not 
occur in IPF PBMCs. Indeed, when comparing healthy and IPF 
PBMCs, we did not observe substantial differences in the release 
of IL-1α. After the stimulation with LPS ± ATP or PolydA:dT the 
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levels of IL-1α from IPF-derived PBMCs were comparable with 
the one from healthy PBMCs. Nevertheless, the basal levels of 
this cytokine were significantly different, higher in healthy than 
IPF. However, when IPF PBMCs were stimulated there was an 
increase from the basal level, compared with the healthy PBMCs, 
which did not induce any increase in the levels of IL-1α. These 
data may imply that a regulatory/protective mechanism occurs 
in healthy PBMCs compared with the pathological condition, 
during which the same values of the cytokine can contribute to 
fibrosis.
On the other hand, we observed that the stimulation of 
another inflammasome receptor AIM2 led to the release of both 
IL-1α and IL-18, but not of IL-1β (not detectable), from PBMCs. 
In this case, though, IL-18 release was caspase-1 dependent, 
compared with IL-1α which instead was caspase-1-, caspase-8 
independent. Various studies demonstrated the involvement of 
IL-18 in the pathogenesis of IPF. IL-18- and IL-18Rα-deficient 
mice were protected from bleomycin-induced lung fibrosis, sug-
gesting a pro-fibrotic role for IL-18 (30). In addition, Kitasato 
et al. reported that IL-18 was expressed in IPF pulmonary cells 
(22). Conversely, other studies suggested a protective role against 
bleomycin-induced lung fibrosis since IL-18 deficient mice had 
higher survival rate than wild-type (31).
In our conditions, because the release of IL-18 via AIM2 was 
similar in both healthy and IPF subjects we believe that the most 
relevant activity of AIM2 during the pathological conditions was 
related to IL-1α. The involvement of IL-1α in chronic lung dis-
eases has been repeatedly reported (11, 32–34). In particular, this 
cytokine is involved in the phenotypic switch of lung fibroblasts 
to their inflammatory state during epithelial damage. Moreover, 
it has been suggested that extracellular IL-1α is an undesiderable 
and potentially harmful factor in fibrotic lung diseases (35). In 
support, IL-1R1−/− and IL-1α−/− mice exhibited reduced BAL 
neutrophilia and collagen deposition in response to bleomycin 
treatment (35) confirming the role of circulating anti-IL-1α 
autoantibodies detected in the blood of IPF patients (36).
In our experimental conditions, IL-1α was neither correlated 
to the caspase-1- and caspase-8-dependent inflammasome activa-
tion, nor to the calpain complex. Rather, it was correlated to AIM2 
activation, caspase-4 extracellular release, and TGF-β release.
TGF-β is a well-known pro-fibrotic and immunosuppressive 
cytokine (23, 24). In IPF, it plays a pivotal role in that it stimulates 
intrapulmonary fibroblasts to express high levels of collagen genes 
and mesenchymal cell-related markers, such as α-smooth muscle 
actin and vimentin (37). Our study is the first, to our knowledge, 
to show that the activation of the AIM2 inflammasome induces 
TGF-β release in an IL-1α-dependent manner. The neutralization 
of IL-1α by means of a monoclonal antibody, significantly redu-
ced the release of TGF-β at 24 h. Differently, two drugs that are 
actually used in therapy (nintedanib and pirfenidone) did not alter 
TGF-β release from PBMCs. More importantly, this effect was not 
dependent on TLR4, rather, it was correlated to caspase-4 release, 
that was not expression of cell death (no differences in LDH levels 
after AIM2 activation). In this context, the extracellular release of 
caspase-4 is associated to cell mortality in literature. Rather, our 
data are the first, to our knowledge, to show that the activation of 
AIM2 leads to caspase-4 release in IPF PBMCs, which were not 
dying cells, but were able to release IL-1α, responsible for TGF β 
levels. In support, the inhibition of TLR4, did not alter both IL-1α 
and TGF-β release from IPF PBMCs. Moreover, AIM2 activation 
via Poly dA:dT increased both mRNA and extracellular release 
of caspase-4. These data, although not a direct evidence, likely 
correlate caspase-4 to the release of IL-1α.
In conclusion, our study focuses on a novel molecular pro-
fibrotic mechanism that underlies the role of AIM2 and caspase-4 
in that the activation of AIM2 leads to the release of pro-inflam-
matory cytokines, such as IL-1α and IL-18, but also to the activa-
tion of a non-canonical inflammasome caspase-4-dependent 
pathway. In particular, we believe that the activation of AIM2 
leads to caspase-4 activation/release with the concomitant release 
of IL-1α responsible of the pro-fibrotic TGF-β levels (Figure 7). 
Although the strict correlation between these pathways still 
remains to be elucidated, we propose novel molecular targets to 
improve survival rate of IPF patients, that unfortunately is still 
very low, due to the lack of efficacy of several therapeutic tools 
(i.e., steroids). To our opinion, we highlighted a novel molecular/
cellular mechanism that can lead to a pro-fibrotic process in IPF 
patients, opening new therapeutic perspectives, especially during 
therapy with nintedanib and pirfenidone that are at the moment 
the sole therapeutic options for IPF patients.
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